First-line (1L) zolbetuximab plus chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT plus GLOW

被引：0

作者：

Kang, Y-K. ^{[1
]}

Shah, M. A. ^{[2
]}

Shitara, K. ^{[3
]}

Ajani, J. A. ^{[4
]}

Lordick, F. ^{[5
]}

Van Cutsem, E. ^{[6
]}

Ilson, D. H. ^{[7
]}

Klempner, S. J. ^{[8
]}

Yamaguchi, K. ^{[9
]}

Nakajima, T. ^{[10
]}

Cao, Y. J. ^{[11
]}

Li, R. ^{[12
]}

Moran, D. ^{[11
]}

Pophale, R. R. ^{[13
]}

Ranganath, R. ^{[13
]}

Xu, R-H. ^{[14
]}

机构：

[1] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[2] Weill Cornell Med Coll, Med Oncol & Hematol Dept, New York, NY USA

[3] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[4] Univ Texas MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA

[5] Univ Krebszentrum Leipzig, Univ Klinikum Leipzig, Med Dept, Leipzig, Germany

[6] UZ Leuven, Univ Hosp Leuven, Digest Oncol Dept, Campus Gasthuisberg, Leuven, Belgium

[7] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Dept Med, New York, NY USA

[8] MGH Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA USA

[9] Canc Inst Hosp JFCR, Gastroenterol Chemotherapy Dept, Koto Ku, Tokyo, Japan

[10] Astellas Pharma Global Dev, Med Dept, Northbrook, IL USA

[11] Astellas Pharma Global Dev Inc, Data Sci, Northbrook, IL USA

[12] Astellas Pharma Global Dev, Data Sci, Northbrook, IL USA

[13] Astellas Pharma Global Dev Inc, Med Affairs Dept, Northbrook, IL USA

[14] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1438P

引用

页码：S895 / S895

页数：1

共 50 条

[1] Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab plus chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.
Shitara, Kohei
Pophale, Rupesh
Matsangou, Maria
Park, Jung Wook
Oh, Mok
Bhattacharya, Pranob P.
Ranganath, Radhika
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 372 - 372
[2] Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-Locally Advanced (LA) Unresectable or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Primary Phase 3 Results From GLOW
Lordick, F.
Xu, R. -H
Shitara, K.
Ajani, J. A.
Bang, Y. -J
Enzinger, P.
Ilson, D.
Van Cutsem, E.
Gallego Plazas, J.
Huang, J.
Shen, L.
Oh, S. C.
Sunpaweravong, P.
Hoo, Soo H. F.
Turk, H. M.
Park, J. W.
Moran, D.
Bhattacharya, P.
Arozullah, A.
Shah, M. A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 116 - 117
[3] Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT Study
Lordick, F.
Shitara, K.
Bang, Y. -J
Enzinger, P.
Ilson, D.
Shah, M. A.
Van Cutsem, E.
Xu, R. -H
Aprile, G.
Xu, J.
Chao, J.
Pazo-Cid, R.
Kang, Y. K.
Yang, J.
Moran, D.
Bhattacharya, P.
Arozullah, A.
Park, J. W.
Ajani, J.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 115 - 116
[4] Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)
Shitara, Kohei
Xu, Rui-Hua
Moran, Diarmuid Martin
Guerrero, Abraham
Li, Ran
Pavese, Janet
Matsangou, Maria
Bhattacharya, Pranob P.
Ajani, Jaffer A.
Shah, Manish A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
Xu, Rui-Hua
Shitara, Kohei
Ajani, Jaffer A.
Bang, Yung-Jue
Enzinger, Peter C.
Ilson, David H.
Lordick, Florian
Van Cutsem, Eric
Gallego Plazas, Javier
Huang, Jing
Shen, Lin
Oh, Sang Cheul
Sunpaweravong, Patrapim
Soo Hoo, Hwoei Fen
Turk, Haci M.
Park, Jung Wook
Moran, Diarmuid Martin
Bhattacharya, Pranob P.
Arozullah, Ahsan
Shah, Manish A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 405736 - 405736
[6] GLOW: Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin18.2./HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Xu, R-H.
Ajani, J. A.
Al-Batran, S-E.
Bang, Y-J.
Catenacci, D.
Enzinger, P. C.
Ilson, D. H.
Kim, S.
Lordick, F.
Shitara, K.
van Cutsem, E.
Arozullah, A.
Park, J. W.
Shah, M. A.
ANNALS OF ONCOLOGY, 2020, 31 : S1315 - S1316
[7] Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER22, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Shitara, Kohei
Van Cutsem, Eric
Lordick, Florian
Enzinger, Peter C.
Ilson, David H.
Shah, Manish A.
Xu, Rui-Hua
Lonardi, Sara
Yamaguchi, Kensei
Hung, Yi-Ping
Kukielka-Budny, Bozena
Bhattacharya, Pranob P.
Matsangou, Maria
Li, Ran
Moran, Diarmuid Martin
Ranganath, Radhika
Pophale, Rupesh
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER22locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
Xu, Rui-hua
Shitara, Kohei
Ajani, Jaffer A.
Bang, Yung-Jue
Enzinger, Peter C.
Ilson, David H.
Lordick, Florian
Van Cutsem, Eric
Plazas, Javier Gallego
Huang, Jing
Shen, Lin
Oh, Sang Cheul
Sunpaweravong, Patrapim
Hoo, Hwoei Fen Soo
Turk, Haci M.
Park, Jung Wook
Moran, Diarmuid Martin
Bhattacharya, Pranob P.
Arozullah, Ahsan
Shah, Manish A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[9] Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+) / HER22 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
Shitara, Kohei
Lordick, Florian
Bang, Yung-Jue
Enzinger, Peter C.
Ilson, David H.
Shah, Manish A.
Van Cutsem, Eric
Xu, Rui-hua
Aprile, Giuseppe
Xu, Jianming
Chao, Joseph
Pazo-Cid, Roberto
Kang, Yoon-Koo
Yang, Jianning
Moran, Diarmuid Martin
Bhattacharya, Pranob P.
Arozullah, Ahsan
Park, Jung Wook
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA292 - LBA292
[10] GLOW: Randomized phase III study of zolbetuximab plus CAPOX compared with placebo plus CAPOX as first-line treatment of patients with CLD18.2+/HER2- locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Shah, M.
Ajani, J. A.
Al-Batran, S-E.
Bang, Y-J.
Catenacci, D. V.
Enzinger, P.
Ilson, D.
Kim, S.
Lordick, F.
Shitara, K.
Van Cutsem, E.
Arozullah, A.
Park, J. W.
Xu, R-H.
ANNALS OF ONCOLOGY, 2019, 30 : 322 - 322

← 1 2 3 4 5 →